USPTO serial 79335933
FEXUCLUE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 1, 2023
- Examiner
- OSGOOD, KRYSTINA E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with FEXUCLUE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Diane J. Mason
Diane J. Mason Faegre Drinker Biddle & Reath LLPFour Embarcadero Center, 27th FloorSan Francisco, CA 94111UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; Pharmaceutical preparations in the nature of proton-pump inhibitors for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; medicines for the treatment of gastrointestinal diseases; medicines for human purposes for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; ethical medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by DAEWOONG PHARMACEUTICAL CO., LTD.
- Other trademarks owned by DAEWOONG PHARMACEUTICAL CO., LTD.
- Other trademarks owned by DAEWOONG PHARMACEUTICAL CO., LTD.
- Other trademarks in Class 005
- Similar marks named FEXUCLUE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 27, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 10, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 2, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 1, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 1, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 1, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 1, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 17, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| May 16, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 16, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 26, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 26, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 26, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 13, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 20, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 17, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 17, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 1, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 12, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 12, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 2, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 1, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 28, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 22, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 18, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 17, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |